disease interaction(s) of Parkinson's disease with age-related macular degeneration
Jump to navigation
Jump to search
Introduction
Interactions:
- dopamine receptor agonists or L-dopa/dopa-decarboxylase inhibitor (Sinemet) used in treatment of Parkinson's disease increases dopamine-signaling via dopamine D2 receptors (DRD2) inhibiting choroidal neovascularization thus delaying neovascular (wet) age-related macular degeneration[1]
More general terms
References
- ↑ 1.0 1.1 Mathis T, Baudin F, Mariet AS et al DRD2 activation inhibits choroidal neovascularization in patients with Parkinson's disease and age-related macular degeneration. J Clin Invest. 2024 Jul 16;134(17):e174199. doi:http://dx.doi.org/ 10.1172/JCI174199. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39012703 PMCID: PMC11364393 Free PMC article.